Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease. (April 2018)

• Record Type: Journal Article
• Authors: Førland, Marthe Gurine; Öhrfelt, Annika; Dalen, Ingvild; Tysnes, Ole-Bjørn; Blennow, Kaj; Zetterberg, Henrik; Pedersen, Kenn Freddy; Alves, Guido; Lange, Johannes
• Is Part Of: Parkinsonism & related disorders. Volume 49(2018)
• Page Start: 4
• Page End: 8
• Publication Date: 2018-04
• Subjects: α-synuclein -- Cerebrospinal fluid -- Biomarker -- Longitudinal measurements -- Parkinson's disease; Parkinson's disease -- Periodicals; Movement disorders -- Periodicals; Movement Disorders -- Periodicals; Nerve Degeneration -- Periodicals; Nervous System Diseases -- Periodicals; Parkinson Disease -- Periodicals; Tremor -- Periodicals; Parkinson, Maladie de -- Périodiques; Parkinson's disease; 616.833
• DOI: 10.1016/j.parkreldis.2018.01.018
• Languages: English
• ISSNs: 1353-8020

Abstract

Abstract: Introduction: Cerebrospinal fluid (CSF) total α-synuclein is considered a potential biomarker for Parkinson's disease (PD), but little is known about the evolution of this marker during the course of the disease. Our objective was to investigate whether CSF total α-synuclein concentrations change over time and are associated with motor and cognitive function in PD. Methods: CSF total α-synuclein concentrations were quantified in 56 longitudinally followed PD patients, 27 of whom provided CSF repeatedly 2 and/or 4 years later. Another 18 subjects were included as controls. The samples were analyzed using two independent, validated ELISA methods: our recently developed and validated in-house ELISA and a commercial kit from BioLegend. Results: CSF total α-synuclein levels did not distinguish PD patients from controls, displayed no substantial changes during a period of up to 4 years, and did not predict subsequent motor or cognitive decline. These findings were consistent for both analytical methods. Conclusion: Our findings do not support the clinical utility of total α-synuclein as a single diagnostic or prognostic biomarker in PD. Highlights: α-synuclein (α-syn) is considered a potential biomarker for PD. Little is known about the evolution of this marker during the course of PD. Our study covers the longest follow-up period so far and used 2 independent methods. α-syn concentrations in PD were similar to controls and did not change over 4 years. α-syn did not predict motor and cognitive decline.